Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2012

Open Access 01-12-2012 | Research article

Murine CD4+CD25- cells activated in vitro with PMA/ionomycin and anti-CD3 acquire regulatory function and ameliorate experimental colitis in vivo

Published in: BMC Gastroenterology | Issue 1/2012

Login to get access

Abstract

Background

Induced regulatory T (iTreg) lymphocytes show promise for application in the treatment of allergic, autoimmune and inflammatory disorders. iTreg cells demonstrate advantages over natural Treg (nTreg) cells in terms of increased number of starting population and greater potential to proliferate. Different activation methods to generate iTreg cells result in iTreg cells that are heterogeneous in phenotype and mechanisms of suppression. Therefore it is of interest to explore new techniques to generate iTreg cells and to determine their physiological relevance.

Methods

Using phorbol myristate acetate (PMA)/ionomycin and anti-CD3 activation of CD4+CD25- cells we generated in vitro functional CD4+CD25+ iTreg (TregPMA) cells. Functionality of the generated TregPMA cells was tested in vivo in a mouse model of inflammatory bowel disease (IBD) - CD45RB transfer colitis model.

Results

TregPMA cells expressed regulatory markers and proved to ameliorate the disease phenotype in murine CD45RB transfer colitis model. The body weight loss and disease activity scores for TregPMA treated mice were reduced when compared to diseased control group. Histological assessment of colon sections confirmed amelioration of the disease phenotype. Additionally, cytokine analysis showed decreased levels of proinflammatory colonic and plasma IL-6, colonic IL-1 β and higher levels of colonic IL-17 when compared to diseased control group.

Conclusions

This study identifies a new method to generate in vitro iTreg cells (TregPMA cells) which physiological efficacy has been demonstrated in vivo.
Appendix
Available only for authorised users
Literature
1.
DiPaolo RJ, Glass DD, Bijwaard KE, Shevach EM: CD4 + CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells. J Immunol. 2005, 175: 7135-7142.CrossRefPubMed
2.
Huter EN, Stummvoll GH, DiPaolo RJ, Glass DD, Shevach EM: Cutting edge: antigen-specific TGF beta-induced regulatory T cells suppress Th17-mediated autoimmune disease. J Immunol. 2008, 181: 8209-8213.CrossRefPubMedPubMedCentral
3.
Kohm AP, Carpentier PA, Anger HA, Miller SD: Cutting edge: CD4 + CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol. 2002, 169: 4712-4716.CrossRefPubMed
4.
Ly D, Mi QS, Hussain S, Delovitch TL: Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4 + CD25+ regulatory T cells. J Immunol. 2006, 177: 3695-3704.CrossRefPubMed
5.
Manirarora JN, Kosiewicz MM, Parnell SA, Alard P: APC activation restores functional CD4(+)CD25(+) regulatory T cells in NOD mice that can prevent diabetes development. PLoS One. 2008, 3: e3739-10.1371/journal.pone.0003739.CrossRefPubMedPubMedCentral
6.
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995, 155: 1151-1164.PubMed
7.
Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI: Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol. 2006, 177: 1451-1459.CrossRefPubMed
8.
Wang S, Xu H, Wang Y, Ma J, Mao C, Shao Q, et al: Regulatory T cells induced by rAAV carrying the forkhead box P3 gene prevent autoimmune thyroiditis in mice. Int J Mol Med. 2006, 18: 1193-1199.PubMed
9.
Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997, 389: 737-742. 10.1038/39614.CrossRefPubMed
10.
Mottet C, Uhlig HH, Powrie F: Cutting edge: cure of colitis by CD4 + CD25+ regulatory T cells. J Immunol. 2003, 170: 3939-3943.CrossRefPubMed
11.
Trzonkowski P, Bieniaszewska M, Juscinska J, Dobyszuk A, Krzystyniak A, Marek N, et al: First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4 + CD25 + CD127- T regulatory cells. Clin Immunol. 2009, 133: 22-26. 10.1016/j.clim.2009.06.001.CrossRefPubMed
12.
Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, et al: Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011, 117: 1061-1070. 10.1182/blood-2010-07-293795.CrossRefPubMedPubMedCentral
13.
Marek N, Bieniaszewska M, Krzystyniak A, Juscinska J, Mysliwska J, Witkowski P, et al: The time is crucial for exvivo expansion of T regulatory cells for therapy. Cell Transplant. 2011, in press
14.
Taams LS, Vukmanovic-Stejic M, Smith J, Dunne PJ, Fletcher JM, Plunkett FJ, et al: Antigen-specific T cell suppression by human CD4 + CD25+ regulatory T cells. Eur J Immunol. 2002, 32: 1621-1630. 10.1002/1521-4141(200206)32:6<1621::AID-IMMU1621>3.0.CO;2-Q.CrossRefPubMed
15.
Hippen KL, Merkel SC, Schirm DK, Nelson C, Tennis NC, Riley JL, et al: Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am J Transplant. 2011, 11: 1148-1157. 10.1111/j.1600-6143.2011.03558.x.CrossRefPubMedPubMedCentral
16.
Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, et al: Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol. 2007, 19: 345-354. 10.1093/intimm/dxm014.CrossRefPubMed
17.
Takahama Y, Nakauchi H: Phorbol ester and calcium ionophore can replace TCR signals that induce positive selection of CD4 T cells. J Immunol. 1996, 157: 1508-1513.PubMed
18.
Wing K, Yamaguchi T, Sakaguchi S: Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol. 2011, 32: 428-433. 10.1016/j.it.2011.06.002.CrossRefPubMed
19.
Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al: CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008, 322: 271-275. 10.1126/science.1160062.CrossRefPubMed
20.
Wang R, Wan Q, Kozhaya L, Fujii H, Unutmaz D: Identification of a regulatory T cell specific cell surface molecule that mediates suppressive signals and induces Foxp3 expression. PLoS One. 2008, 3: e2705-10.1371/journal.pone.0002705.CrossRefPubMedPubMedCentral
21.
Wang R, Kozhaya L, Mercer F, Khaitan A, Fujii H, Unutmaz D: Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A. 2009, 106: 13439-13444.CrossRefPubMedPubMedCentral
22.
Vocanson M, Rozieres A, Hennino A, Poyet G, Gaillard V, Renaudineau S, et al: Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells. J Allergy Clin Immunol. 2010, 126: 280-289. 10.1016/j.jaci.2010.05.022.CrossRefPubMed
23.
Niedbala W, Cai B, Liu H, Pitman N, Chang L, Liew FY: Nitric oxide induces CD4 + CD25+ Foxp3- regulatory T cells from CD4 + CD25- T cells via p53, IL-2, and OX40. Proc Natl Acad Sci U S A. 2007, 104: 15478-15483. 10.1073/pnas.0703725104.CrossRefPubMedPubMedCentral
24.
Leach MW, Bean AG, Mauze S, Coffman RL, Powrie F: Inflammatory bowel disease in C.B-17 scid mice reconstituted with the CD45RBhigh subset of CD4+ T cells. Am J Pathol. 1996, 148: 1503-1515.PubMedPubMedCentral
25.
Morrissey PJ, Charrier K, Braddy S, Liggitt D, Watson JD: CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J Exp Med. 1993, 178: 237-244. 10.1084/jem.178.1.237.CrossRefPubMed
26.
Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL: Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol. 1993, 5: 1461-1471. 10.1093/intimm/5.11.1461.CrossRefPubMed
27.
Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL: Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994, 1: 553-562. 10.1016/1074-7613(94)90045-0.CrossRefPubMed
28.
Hirano D, Kudo S: Usefulness of CD4 + CD45RBhighCD25- Cell- Transferred SCID Mice for Preclinical Evaluation of Drugs for Inflammatory Bowel Disease. J Pharmacol Sci. 2009, 110: 169-181. 10.1254/jphs.08293FP.CrossRefPubMed
29.
Kanai T, Kawamura T, Dohi T, Makita S, Nemoto Y, Totsuka T, et al: TH1/TH2-mediated colitis induced by adoptive transfer of CD4 + CD45RBhigh T lymphocytes into nude mice. Inflamm Bowel Dis. 2006, 12: 89-99. 10.1097/01.MIB.0000197237.21387.mL.CrossRefPubMed
30.
O'Connor W, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, et al: A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol. 2009, 10: 603-609. 10.1038/ni.1736.CrossRefPubMedPubMedCentral
31.
van Montfrans C, Rodriguez Pena MS, Pronk I, Ten Kate FJ, Te Velde AA, van Deventer SJ: Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model. Gastroenterology. 2002, 123: 1865-1876. 10.1053/gast.2002.37067.CrossRefPubMed
32.
Kanai T, Mikami Y, Sujino T, Hisamatsu T, Hibi T: RORgammat-dependent IL-17A-producing cells in the pathogenesis of intestinal inflammation. Mucosal Immunol. 2012, 5: 240-247. 10.1038/mi.2012.6.CrossRefPubMed
33.
O'Connor W, Zenewicz LA, Flavell RA: The dual nature of T(H)17 cells: shifting the focus to function. Nat Immunol. 2010, 11: 471-476. 10.1038/ni.1882.CrossRefPubMed
34.
Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y: Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol. 2004, 110: 55-62. 10.1016/j.clim.2003.09.013.CrossRefPubMed
35.
Park YH, Koo SK, Kim Y, Kim HM, Joe IY, Park CS, et al: Effect of in vitro expanded CD4(+)CD25(+)Foxp3(+) regulatory T cell therapy combined with lymphodepletion in murine skin allotransplantation. Clin Immunol. 2010, 135: 43-54. 10.1016/j.clim.2009.11.011.CrossRefPubMed
36.
Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al: IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010, 11: 1093-1101. 10.1038/ni.1952.CrossRefPubMedPubMedCentral
37.
Lu L, Zhou X, Wang J, Zheng SG, Horwitz DA: Characterization of protective human CD4CD25 FOXP3 regulatory T cells generated with IL-2. TGF-beta and retinoic acid. PLoS One. 2010, 5: e15150-10.1371/journal.pone.0015150.CrossRefPubMedPubMedCentral
38.
Frey MR, Leontieva O, Watters DJ, Black JD: Stimulation of protein kinase C-dependent and -independent signaling pathways by bistratene A in intestinal epithelial cells. Biochem Pharmacol. 2001, 61: 1093-1100. 10.1016/S0006-2952(01)00596-2.CrossRefPubMedPubMedCentral
39.
Dadsetan S, Shishkin V, Fomina AF: Intracellular Ca(2+) release triggers translocation of membrane marker FM1-43 from the extracellular leaflet of plasma membrane into endoplasmic reticulum in T lymphocytes. J Biol Chem. 2005, 280: 16377-16382. 10.1074/jbc.M501202200.CrossRefPubMed
40.
Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA: CD4 + CD25high regulatory cells in human peripheral blood. J Immunol. 2001, 167: 1245-1253.CrossRefPubMed
41.
Oh-Hora M, Yamashita M, Hogan PG, Sharma S, Lamperti E, Chung W, et al: Dual functions for the endoplasmic reticulum calcium sensors STIM1 and STIM2 in T cell activation and tolerance. Nat Immunol. 2008, 9: 432-443. 10.1038/ni1574.CrossRefPubMedPubMedCentral
42.
Oh-Hora M, Rao A: The calcium/NFAT pathway: role in development and function of regulatory T cells. Microbes Infect. 2009, 11: 612-619. 10.1016/j.micinf.2009.04.008.CrossRefPubMedPubMedCentral
43.
Malek TR, Castro I: Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010, 33: 153-165. 10.1016/j.immuni.2010.08.004.CrossRefPubMedPubMedCentral
44.
Nishio J, Feuerer M, Wong J, Mathis D, Benoist C: Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints. J Exp Med. 2010, 207: 1879-1889. 10.1084/jem.20100205.CrossRefPubMedPubMedCentral
45.
Chen M, Xiao X, Demirci G, Li XC: OX40 controls islet allograft tolerance in CD154 deficient mice by regulating FOXP3+ Tregs. Transplantation. 2008, 85: 1659-1662. 10.1097/TP.0b013e3181726987.CrossRefPubMed
46.
Griseri T, Asquith M, Thompson C, Powrie F: OX40 is required for regulatory T cell-mediated control of colitis. J Exp Med. 2010, 207: 699-709. 10.1084/jem.20091618.CrossRefPubMedPubMedCentral
47.
Barthlott T, Kassiotis G, Stockinger B: T cell regulation as a side effect of homeostasis and competition. J Exp Med. 2003, 197: 451-460. 10.1084/jem.20021387.CrossRefPubMedPubMedCentral
48.
Dinarello CA: Interleukin-1. Cytokine Growth Factor Rev. 1997, 8: 253-265. 10.1016/S1359-6101(97)00023-3.CrossRefPubMed
49.
Te Velde AA, de Kort F, Sterrenburg E, Pronk I, Ten Kate FJ, Hommes DW, et al: Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm Bowel Dis. 2007, 13: 325-330. 10.1002/ibd.20079.CrossRefPubMed
50.
Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK: Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008, 14: 4280-4288. 10.3748/wjg.14.4280.CrossRefPubMedPubMedCentral
51.
Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, et al: Regulation of inflammatory responses by IL-17 F. J Exp Med. 2008, 205: 1063-1075. 10.1084/jem.20071978.CrossRefPubMedPubMedCentral
52.
Voo KS, Wang YH, Santori FR, Boggiano C, Wang YH, Arima K, et al: Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A. 2009, 106: 4793-4798. 10.1073/pnas.0900408106.CrossRefPubMedPubMedCentral
53.
van der Marel S, Majowicz A, van Deventer S, Petry H, Hommes DW, Ferreira V: Gene and cell therapy based treatment strategies for inflammatory bowel diseases. World J Gastrointest Pathophysiol. 2011, 2: 114-122. 10.4291/wjgp.v2.i6.114.CrossRefPubMedPubMedCentral
54.
Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ: All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med. 2007, 204: 1765-1774. 10.1084/jem.20070719.CrossRefPubMedPubMedCentral
55.
Karlsson F, Robinson-Jackson SA, Gray L, Zhang S, Grisham MB: Ex vivo generation of regulatory T cells: characterization and therapeutic evaluation in a model of chronic colitis. Methods Mol Biol. 2011, 677: 47-61.CrossRefPubMedPubMedCentral
Metadata
Title
Murine CD4+CD25- cells activated in vitro with PMA/ionomycin and anti-CD3 acquire regulatory function and ameliorate experimental colitis in vivo
Publication date
01-12-2012
Published in
BMC Gastroenterology / Issue 1/2012
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-12-172

Other articles of this Issue 1/2012

BMC Gastroenterology 1/2012 Go to the issue

Research article

Factors associated with consultation behaviour for primary symptoms potentially indicating colorectal cancer: A cross-sectional study on response to symptoms

Research article

The Zelnorm epidemiologic study (ZEST): a cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment

Research article

Evaluation of patient satisfaction of an outpatient gastroscopy service in an Asian tertiary care hospital

Research article

Effectiveness of CO2-insufflated endoscopic submucosal dissection with the duodenal balloon occlusion method for early esophageal or gastric cancer: a randomized case control prospective study

Research article

Patients who take their symptoms less seriously are more likely to have colorectal cancer

Research article

Evaluation of ES-derived neural progenitors as a potential source for cell replacement therapy in the gut

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits